Federation Des Caisses Desjardins Du Quebec Alnylam Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 18,816 shares of ALNY stock, worth $4.85 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

18,816

Previous 15,981 17.74%

Holding current value

$4.85 Million

Previous $3.88 Million 33.27%

% of portfolio

0.03%

Previous 0.02%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $662,851 - $813,673	2,835 Added 17.74%	18,816 $5.18 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $100,890 - $173,888	-704 Reduced 4.22%	15,981 $3.88 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $2.44 Million - $3.31 Million	16,685 New	16,685 $3.17 Billion
Q3 2023 Aug 14, 2024	SELL	$170.77 - $211.65 $199,288 - $246,995	-1,167 Reduced 6.78%	16,039 $2.84 Billion
Q2 2023 Aug 14, 2024	SELL	$185.01 - $212.05 $1.86 Million - $2.14 Million	-10,069 Reduced 36.92%	17,206 $3.27 Billion
Q1 2023 Aug 14, 2024	SELL	$182.66 - $235.53 $1.17 Million - $1.51 Million	-6,424 Reduced 19.06%	27,275 $5.46 Billion
Q3 2022 Aug 14, 2024	SELL	$138.54 - $232.0 $111,663 - $186,992	-806 Reduced 2.34%	33,699 $6.75 Billion
Q2 2022 Aug 14, 2024	BUY	$120.42 - $169.29 $111,990 - $157,439	930 Added 2.77%	34,505 $5.03 Billion
Q1 2022 Aug 14, 2024	BUY	$127.18 - $173.91 $2.24 Million - $3.06 Million	17,594 Added 110.09%	33,575 $5.48 Billion
Q4 2021 Aug 30, 2024	SELL	$159.56 - $209.29 $250,349 - $328,376	-1,569 Reduced 4.61%	32,446 $5.5 Billion
Q3 2021 Aug 30, 2024	SELL	$169.75 - $207.73 $269,393 - $329,667	-1,587 Reduced 4.46%	34,015 $6.42 Billion
Q2 2021 Aug 30, 2024	BUY	$128.63 - $176.89 $2.52 Million - $3.47 Million	19,621 Added 122.78%	35,602 $6.03 Billion
Q1 2021 Aug 30, 2024	SELL	$126.83 - $175.69 $1.3 Million - $1.8 Million	-10,223 Reduced 21.95%	36,347 $5.13 Billion
Q4 2020 Aug 30, 2024	SELL	$122.97 - $147.0 $634,402 - $758,373	-5,159 Reduced 9.97%	46,570 $6.06 Billion
Q3 2020 Aug 30, 2024	SELL	$121.19 - $165.49 $535,296 - $730,969	-4,417 Reduced 7.87%	51,729 $7.55 Billion
Q2 2020 Aug 30, 2024	SELL	$104.21 - $156.44 $345,039 - $517,972	-3,311 Reduced 5.57%	56,146 $8.34 Billion
Q4 2019 Aug 30, 2024	BUY	$74.51 - $124.23 $243,647 - $406,232	3,270 Added 5.82%	59,457 $6.84 Billion
Q3 2019 Aug 30, 2024	BUY	$70.9 - $87.82 $1.79 Million - $2.22 Million	25,295 Added 81.88%	56,187 $4.52 Billion
Q1 2019 Aug 30, 2024	BUY	$72.76 - $93.45 $554,140 - $711,715	7,616 Added 32.72%	30,892 $2.89 Billion
Q4 2018 Aug 30, 2024	BUY	$62.67 - $88.33 $457,177 - $644,367	7,295 Added 45.65%	23,276 $1.7 Billion
Q2 2017 Aug 30, 2024	SELL	N/A	-3,536 Reduced 13.19%	23,276 $1.86 Billion
Q1 2017 Aug 30, 2024	BUY	N/A	10,831	26,812 $1.37 Billion

Others Institutions Holding ALNY

# of Institutions

639

Shares Held

108M

Call Options Held

1.15M

Put Options Held

1.07M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account

Federation Des Caisses Desjardins Du Quebec Alnylam Pharmaceuticals, Inc. Transaction History